Condition
Obesity Associated With Defects in Leptin-melanocortin Pathway
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by Setmelanotide
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Phase 2/3 (1)
Phase 3 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT06596135Phase 3CompletedPrimary
Open-Label Extension Study of Setmelanotide
NCT03651765Phase 2/3CompletedPrimary
Long Term Extension Trial of Setmelanotide
Showing all 2 trials
Research Network
Common Treatments
- Setmelanotide2
Active Sponsors
- Rhythm Pharmaceuticals, Inc.2
Top Investigators
Rhythm Pharmaceuticals, Inc.